Podcasts about Breast cancer

Diet plans. Supplements. Protocols. Podcasts. Advice from well-meaning people. At some point, all of that support can stop feeling helpful and start feeling overwhelming. In this episode, Laura shares a real-life story that highlights how stress and unresolved trauma can impact metabolic health, even when diet and exercise look "right." She explains why consistency, tracking data, and self-honesty matter so much when making changes, and how constantly switching approaches can keep us stuck. This episode offers permission to slow down, turn down the noise, and focus on what truly supports healing after breast cancer.   Let's Connect! If this episode helped you breathe a little easier, please share it with a friend or leave a review. Every share helps spread this message of hope, healing, and whole-person wellness.

Breast cancer is being diagnosed in younger women more than in the past. There is new research that explores how physical activity may lower future breast cancer risk for girls. Adult women who are highly engaged in recreational physical activity have a roughly 20% reduction in breast cancer risk compared to less active women, according to reporting in the Deseret News. Lois Collins, with the Deseret News joins the show to explain the details.

When Dr. Elizabeth Boham was diagnosed with aggressive triple negative breast cancer at just 30 -- during her medical residency, with no family history -- what she later discovered years later through functional medicine were the forces that might have led to her and countless others being susceptible to developing breast cancer. Today, with decades of regained health and of caring for patients, Dr. Boham is a wealth of knowledge, experience and practicality. We dive into small steps we can take to address some of the key drivers of breast wellness, so join us for this uplifting and empowering conversation!   LET'S TALK THE WALK! Join here for support, motivation and fun! Wellness While Walking Facebook page Walking to Wellness Together Facebook GROUP Wellness While Walking on Instagram Wellness While Walking on Threads Wellness While Walking on Twitter Wellness While Walking website for show notes and other information wellnesswhilewalking@gmail.com   RESOURCES AND SOURCES (some links may be affiliate links) DR. ELIZABETH BOHAM, MD MS RD, IFMCP Breast Wellness: Tools to Prevent and Heal From Breast Cancer Kindle edition Paperback edition Dr. Boham's 15 Tips for Breast Wellness Dr. Boham's Website Dr. Boham on Instagram The UltraWellness Center, Lenox, MA (Caring for patients worldwide) Main Page  About the Team, Including Medical Director Dr. Elizabeth Boham Clinical Approach  How to Work with The UltraWellness Center    HEALTH COACH CAROLYN Get on the waitlist for the first Lifestyle Change Workshop of 2026: Email wellnesswhilewalking@gmail.com with your interest (but no obligation)! Details to follow Past Wellness While Walking Episodes with Dr. Boham Ep. 32: Reducing Inflammation for Optimal Health Ep. 33: Food as Medicine, Gratitude, Movement + More   HOW TO RATE AND REVIEW WELLNESS WHILE WALKING How to Leave a Review on Apple Podcasts on Your iOS Device 1.   Open Apple Podcast App (purple app icon that says Podcasts). 2.   Go to the icons at the bottom of the screen and choose "search" 3.   Search for "Wellness While Walking" 4.   Click on the SHOW, not the episode. 5.   Scroll all the way down to "Ratings and Reviews" section 6.   Click on "Write a Review" (if you don't see that option, click on "See All" first) 7.   Then you will be able to rate the show on a five-star scale (5 is highest rating) and write a review! 8.   Thank you! I so appreciate this!   How to Leave a Review on Apple Podcasts on a Computer  1.   Visit Wellness While Walking page on Apple Podcasts in your web browser (search for Apple Podcasts or click here)  https://www.apple.com/apple-podcasts/ 2.   Click on "Listen on Apple Podcasts" or "Open the App" 3.   This will open Apple Podcasts and put in search bar at top left "Wellness While Walking" 4.   This should bring you to the show, not a particular episode – click on the show's artwork 5.   Scroll down until you see "Rating and Reviews" 6.   Click on "See All" all the way to the right, near the Ratings and Review Section and its bar chart 7.   To leave a written review, please click on "Write a Review" 8.   You'll be able to leave a review, along with a title for it, plus you'll be able to rate the show on the 5-star scale (with 5 being the highest rating) 9.   Thank you so very much!! OTHER APPS WHERE RATINGS OR REVIEWS ARE POSSIBLE Spotify Goodpods Overcast (if you star certain episodes, or every one, that will help others find the show)  Castbox Podcast Addict Podchaser Podbean   HOW TO SHARE WELLNESS WHILE WALKING Tell a friend or family member about Wellness While Walking, maybe while you're walking together or lamenting not feeling 100% Follow up with a quick text with more info, as noted below! (My favorite is pod.link/walking because it works with all the apps!) Screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Wellness While Walking on Apple – click the up arrow to share with a friend via text or email, or share to social media Wellness While Walking on Spotify -- click the up arrow to share with a friend via text or email, or share to social media Use this universal link for any podcast app: pod.link/walking – give it to friends or share on social media Tell your pal about the Wellness While Walking website Thanks for listening and now for sharing! : )       DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking.     Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!

Marybeth was diagnosed with stage 0 ER+, HER2+ breast cancer in 2007 at age 39, and 13 years later learned her cancer had metastasized to her bones and lymph system. At her therapist's suggestion, she read Radical Remission, which gave her hope, shifted her mindset, and showed her that healing beyond the statistics was possible. The book propelled her to explore peer-reviewed research and adopt powerful anti-cancer strategies. Within three months she achieved a complete pathological response, and she has now been cancer-free for more than five years. Outperform Cancer Website: www.outperformcancer.com Outperform Cancer Podcast on Apple and Spotify Facebook: https://www.facebook.com/outperformcancer Instagram: https://www.instagram.com/marybethgilliam Threads: https://www.threads.com/@marybethgilliam X: https://x.com/marybethgilliam Blue Sky: https://bsky.app/profile/outperformcancer.bsky.social Resources: American Association for Cancer Research (AACR)-https://www.aacr.org/ National Breast Cancer Coalition (NBCC)-https://www.stopbreastcancer.org/ ___________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube _______________

In this episode of Keeping Abreast, Dr. Jenn Simmons is joined by Dr. Eugene Shippen, hormone specialist best known for his early work in bioidentical hormone therapy and for authoring The Testosterone Syndrome. Together, they explore the overlooked biology behind endometriosis, breast cancer, and persistent hormonal imbalance, focusing on how aromatase-driven inflammation links these conditions and why standard treatments often miss the root cause.The conversation covers individualized vitamin D dosing, iodine's role in thyroid and breast health, testosterone in women, and a clear, evidence-based approach to hormone replacement therapy, who it's right for, who should avoid it, and why many women are being denied care unnecessarily.In This Episode, You'll Learn:How estrogen and inflammation drive hormone-positive breast cancerWhy breast tumors produce their own estrogen and what treatment often overlooksWhat endometriosis reveals about aromatase activity and breast cancer biologyWhy vitamin D functions as a hormone and how deficiency impacts breast cancer risk and outcomesThe role of iodine in breast tissue, dense breasts, and fibrocystic diseaseWhen hormone replacement therapy may be appropriate after breast cancer and when it is notEpisode Timeline00:00 Introduction to Hormonal Health05:06 Understanding Endometriosis12:28 Endometriosis and Breast Cancer Connections17:33 The Coimbra Protocol and Vitamin D22:15 Vitamin D's Role in Disease Prevention27:55 Individualized Vitamin D Dosing35:39 Monitoring Health Conditions37:03 The Role of Testosterone in Women's Health42:46 Understanding Iodine and Its Importance50:50 Hormone Replacement Therapy: Current Perspectives01:00:18 Breast Cancer and Hormone Replacement01:03:39 Environmental Factors Influencing Breast Cancer RatesTo talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.jennsimmonsmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

Today I spoke with Anna Fishzon about her new book The Impossible Return - Psychoanalytic Reflections on Breast Cancer, Loss, and Mourning (Routledge, 2025). The Impossible Return is a hybrid work of cancer memoir, psychoanalytic theory, and Soviet history that explores the author's experience with breast cancer through the lens of mourning, loss, and identity. Fishzon weaves together her personal narrative of mastectomy and reconstruction with psychoanalytic concepts—particularly the uncanny, shame, and the impossibility of fully mourning what has been lost—while drawing connections to her late Soviet Ukrainian childhood and her deep engagement with opera. The book examines how the reconstructed breast becomes an uncanny double, how the prosthetic oscillates between absence and presence, and how cancer survivorship involves living with "scanxiety" and perpetual waiting. Through this autotheoretical approach, Fishzon explores broader questions about memory as scar tissue, the relationship between voice and embodiment, and what she calls the "terribly obscure utopian" work of psychoanalysis—asking the impossible of both analyst and patient, much like perestroika's call for reconstruction. The work treats cancer survival not as a triumph narrative but as an ongoing, repetitive process of attempting to mourn something that remains fundamentally unmournable. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychoanalysis

Today I spoke with Anna Fishzon about her new book The Impossible Return - Psychoanalytic Reflections on Breast Cancer, Loss, and Mourning (Routledge, 2025). The Impossible Return is a hybrid work of cancer memoir, psychoanalytic theory, and Soviet history that explores the author's experience with breast cancer through the lens of mourning, loss, and identity. Fishzon weaves together her personal narrative of mastectomy and reconstruction with psychoanalytic concepts—particularly the uncanny, shame, and the impossibility of fully mourning what has been lost—while drawing connections to her late Soviet Ukrainian childhood and her deep engagement with opera. The book examines how the reconstructed breast becomes an uncanny double, how the prosthetic oscillates between absence and presence, and how cancer survivorship involves living with "scanxiety" and perpetual waiting. Through this autotheoretical approach, Fishzon explores broader questions about memory as scar tissue, the relationship between voice and embodiment, and what she calls the "terribly obscure utopian" work of psychoanalysis—asking the impossible of both analyst and patient, much like perestroika's call for reconstruction. The work treats cancer survival not as a triumph narrative but as an ongoing, repetitive process of attempting to mourn something that remains fundamentally unmournable. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.

In this powerful episode of The Running Wine Mom, Samantha Cieslinski sits down with journalist, filmmaker, and two-time breast cancer survivor Athena Jones for an honest conversation about early detection, self-advocacy, and the racial disparities Black women face in breast cancer outcomes.Diagnosed twice before the age of 40, Athena shares how a baseline mammogram — offered years before standard screening guidelines — changed the course of her life. She opens up about navigating cancer while advancing her career, losing her mother, and learning to trust her body when something didn't feel right.Together, Samantha and Athena explore why breast cancer is often diagnosed younger in Black women, how systemic barriers impact early detection, and what “better” could look like in the future — including risk-based screening and emerging AI tools in healthcare.This episode is a reminder to listen to your body, ask better questions, and never stop advocating for yourself.What You'll Learn in This EpisodeWhy early detection is critical — especially for women under 40How a baseline mammogram helped catch cancer at Stage 0The emotional and mental toll of a second breast cancer diagnosisWhy breast cancer outcomes are worse for Black women — and whyBarriers to screening: insurance, guidelines, bias, and accessWhat self-advocacy in healthcare really looks likeHow community and support can change treatment decisionsWhat gives hope for the future of breast cancer careResources & Links MentionedAthena Jones on Instagram: https://www.instagram.com/iamathenajonesSisters' Keepers Documentary (in production): https://www.sisterskeepersdoc.comSusan G. Komen Foundation: https://www.komen.orgThe Running Wine Mom on Instagram: https://www.instagram.com/therunningwinemom

Today's guest is Sally Orange MBE, former British Army Major and physiotherapist turned fruit dressing adventure athlete, mental health campaigner and charity fundraiser. Diagnosed in 2025 with breast cancer, she has faced her experience with hope, moving forward openly and unapologetically.Sally has completed over 85 marathons, including The London Marathon and the Everest Marathon, both between diagnosis and surgery!! She has completed the 7 marathons on 7 continents in 7 days, and even ran to all of her chemo sessions. We talk about silver linings, mental health challenges, of course running, finding gratitude always, and so much more.I've gotten lots of mental advice for the marathon I will be running this year from Sally, and there are so many great nuggets for life in this conversation. I'm so excited for you all to tune in!Resources:Sally's Website: www.sallyorange.comSally's Instagram: https://www.instagram.com/sallyorangembe/Sally's LinkedIn: https://www.linkedin.com/in/sally-orange-mbe-95948741/Sally's Facebook: https://www.facebook.com/sally.orange.942Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

New research will bring hope to the thousands of women in the UK living with secondary breast cancer. A simple blood test will be able to tell how well they will respond to treatment, even before it starts. This research could mean being moved to more efficient treatments earlier. Nuala McGovern hears from Dr Iseult Browne, one of the researchers on the study. The Grammy award-winning American R&B singer/songwriter and actress, Andra Day, made her acting debut with her portrayal of Billie Holiday in The United States vs. Billie Holiday. Her emotionally raw and transformative performance made her only the second black actress to win the Golden Globe for Best Actress. Her voice first reached a global audience with her anthem Rise Up which earned two Grammy nominations. She joins Nuala to talk about her latest role, as Christine, in the film - Is This Thing On?An employment tribunal ruled on Friday that the dignity of a group of female nurses at Darlington Memorial Hospital was violated because they had to share single-sex changing rooms with a transgender colleague, who was born male but identifies as a woman. BBC's Health Correspondent Dominic Hughes explains further.Today another episode of our SEND in the Spotlight podcast drops, and this one is all about the local authority's role in the SEND system. They come in for a lot of criticism from some of our guests, who feel they need to go to battle with their council in the attempt to get their children's needs met. Rebecca is a SEND mum who is also a SEND caseworker for a local authority. She got in touch because she wanted to talk about the realities of her job. Mattel have just released autistic Barbie. It's the latest in their range of dolls which have included wheelchair and Downs syndrome Barbies. So how do brands use socially conscious products to appeal to consumers, and how much are they targeting women with issues they care about? To discuss Catherine Shuttleworth, CEO of the marketing agency Get Savvy and Dionne Nickerson, Assistant Professor of Marketing at the Goizueta Business School at Emory University in Atlanta, Georgia join Nuala.Presenter: Nuala McGovern Producer: Kirsty Starkey

No one should face breast cancer alone. Luckily, childhood friends Caryn Siegel Finley and Tammy Leyden didn't have to. The two grew up together on Staten Island and have been best friends since they were 7 years old. When they both were diagnosed with breast cancer in their early 40's, just one year apart, they were able to support each other through the process. Caryn and Tammy are here today to share their stories with us and how they are committed to supporting those affected by breast cancer.

How many times have you made the decision to start eating more veggies, skip the junk food and drink enough water, only to abandon that decision within 48 hours? I know how frustrating that is, and I'm on a mission to help you make this the year that you finally adopt healthy, sane nutrition habits that support your goal of eating with peace after breast cancer. Making habit changes, regardless of whether they're about nutrition, fitness or stress (maybe all three?) is something most people want to do, but there's a gap between wanting and doing. Today in Part 3 of Breast Cancer Nutrition Habits: The Clarity Series, I share the reasons why you struggle to start and maintain new nutrition habits, and offer three time-tested tips to help you break that start-stop-beat yourself up cycle so that you feel confident and successful in all your efforts to eat for your breast health.After today's episode you'll understand:Why you fall back into old nutrition habits, even when they don't serve youThe life-changing habit of putting knowledge into actionWhat it really takes to start and maintain new habits for lifeClick here to get the KEEP, START, STOP Plan Worksheet Click here to apply to my Peaceful Plate program! Follow me on Instagram @hormone.breastcancer.dietitian

326. KATRINA LEWIS'S BREAST CANCER SAGA AND TIPS FOR OTHER CANCERS Katrina's cancer was a mystery to me until this post was nearly published. Hint: What should real docs ask every patient first? Resist turning to the end to find out before reading the rest. Support the show

326. KATRINA LEWIS'S BREAST CANCER SAGA AND TIPS FOR OTHER CANCERS Katrina's cancer was a mystery to me until this post was nearly published. Hint: What should real docs ask every patient first? Resist turning to the end to find out before reading the rest. Support the show

Dr. Jenn Simmons is a pioneering force in the world of breast cancer care. Once a renowned breast cancer surgeon, Dr. Jenn transformed her practice after her own journey as a patient, becoming an integrative oncologist with a mission to revolutionize breast cancer diagnosis, treatment, and screening. Dr. Jenn is the author of the best-selling book, "The Smart Woman's Guide to Breast Cancer," hailed as a must-read for anyone navigating this challenging journey. As the host of the insightful podcast "KEEPING ABREAST WITH DR. JENN," she shares her expertise and passion for holistic health. At Perfeqtion Imaging, Dr. Jenn is leading the charge with safe, affordable, and radiation-free breast imaging. Committed to addressing the needs of the forgotten woman, she educates on the safety and benefits of bioidentical hormone replacement therapy for breast cancer survivors, forever changing the landscape of breast health. In this episode, former breast surgeon Dr. Jen Simmons shares how her own breast cancer diagnosis led her to abandon conventional treatments and adopt a holistic, root-cause-focused approach through functional medicine. She critiques mammograms for their radiation risks and limitations, advocating safer alternatives like monthly self-exams, the at-home Aria tears test, and her radiation-free QT scan, while emphasizing true prevention and mindset in healing.   RESOURCES: Learn more about Dr. Jenn Simmons and check out The Breast Health Blueprint here: http://www.realhealthmd.com/ Instagram: @drjennsimmons Get her book The Smart Woman's Guide to Breast Cancer here: https://amzn.to/4jJKSEw Check out her podcast here: https://keepingabreastwithdrjenn.buzzsprout.com/ Get 15% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara   CHAPTERS: 0:00:00 - Introduction & Guest Overview  0:02:22 - Sponsor Segment: Peluva Minimalist Shoes  0:04:18 -Dr. Simmons' Background and Family History with Breast Cancer 0:04:46 - Story of Cousin Linda Creed (Songwriter, "The Greatest Love of All," her death from breast cancer at age 37) 0:05:43 - Dr. Simmons' Career Path (Becoming a doctor, surgeon, fellowship-trained breast surgeon) 0:06:40 - Her Own Health Diagnosis (Hearing treatment recommendations as a patient, leading to a paradigm shift) 0:07:18 - Encounter with Functional Medicine (Attending a lecture by Dr. Mark Hyman, initial skepticism) 0:08:58 - Realizations from Functional Medicine (Root causes, healing vs. symptom treatment, mission to help millions) 0:10:30 - Her Healing Journey and Lessons Learned (Studying functional medicine, mistakes, health as a journey, need for community) 0:12:15 - Criticisms of Conventional Medicine (Loneliness, lack of personalization, no focus on root causes or healing) 0:13:29 - Book Recommendation and Purpose Alignment (The Smart Woman's Guide to Breast Cancer, lifelong alignment with purpose) 0:20:40 - What you should know if you are diagnosed with Breast Cancer 0:56:20 - Mindset and Story Manifestation (Importance of the narrative you tell yourself, subconscious work for full healing) 0:57:01 - Breast Cancer Screening Discussion (Criticism of mammograms, ethics of radiation/gadolinium for healthy women) 0:58:42 - Alternatives to Traditional Screening (Safe, painless options; self-examination instructions) 0:59:41 - The Auria Test (At-home test for inflammatory proteins, sensitivity/specificity, prevention potential, discount code) 1:02:51 - QT Scan and Perfection Imaging (Radiation-free imaging via sound waves, sensitivity, volumetric measuring to avoid unnecessary biopsies) 1:06:59 - Mission to Revolutionize Screening (Plans for expansion, making screening safe and preventative)   WORK WITH TARA: Are You Looking for Help on Your Wellness Journey? Here's how Tara can help you: TRY MY APP FOR FREE: http://taragarrison.com/app INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats   SOCIAL MEDIA:  Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison   INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv   If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the 'Ratings & Reviews' section. Tap 'Write a Review' (you may be prompted to log in with your Apple ID). Thank you!

Send us a textSeason 3 Episode 21A Story of Strength, Honesty, and HopeIn this deeply moving episode, Patrick sits down with Jenny Beards to share her extraordinary journey through breast cancer — from diagnosis to treatment, and everything in between. With openness, courage, and remarkable honesty, Jenny talks us through the moment her world changed, the decisions she faced, and the reality of navigating chemotherapy, radiotherapy, and ultimately a double mastectomy.This is not a sugar-coated story. Jenny speaks candidly about the fear, the physical toll, the emotional lows, and the moments when everything felt overwhelming. But alongside the hard days are stories of resilience, humour, compassion, and the incredible care she received from medical professionals who helped carry her through the toughest chapters.Just as powerfully, Jenny reflects on what comes after — finding strength she never knew she had, rebuilding confidence, and emerging on the other side with a renewed perspective on life. Her journey is one of survival, gratitude, and quiet determination, offering reassurance and hope to anyone facing cancer themselves, supporting a loved one, or wanting to better understand the reality behind the diagnosis.This episode is honest, emotional, and ultimately uplifting — a testament to the human spirit, the importance of early awareness, and the life-changing impact of excellent treatment and support.

Picture this: a patient with early-stage breast cancer is sitting in front of you in the clinic. You are about to offer your expert management plan. The age-old question arises—should you really perform a sentinel lymph node biopsy, or could omission actually help this patient more? Today, we're tackling one of the hottest debates in modern breast cancer care.Should we rethink sentinel lymph node biopsy for select patients, and can skipping it actually improve quality of life without sacrificing cancer control? The stakes couldn't be higher—balancing accurate cancer staging and minimizing harm is the name of the game. Together, we're breaking down the latest evidence from the SOUND and INSEMA trials. What do these landmark studies mean for your patients, your practice, and the future of axillary management? Ready for a journal review that might just change your next consult? Hosts:- Rashmi Kumar, MD, PhDResident, University of Michigan General Surgery Residency ProgramTwitter/X: @RashmiJKumar- Melissa Pilewskie, MDAttending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine Twitter/X: @MPilewskie- Stephanie Downs-Canner, MDAttending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program Twitter/X: @SDownsCannerLearning Objectives:- Understand when and for whom it is safe and beneficial to omit sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients.- Identify the risks associated with foregoing SLNB, including loss of nodal staging, and analyze how this impacts treatment selection and prognosis.- Review key findings from the SOUND and INSEMA trials and their influence on axillary management.- Discuss implications for adjuvant therapy, genomic profiling, and multidisciplinary clinical practice.- Recognize which patient populations should still receive SLNB, and the importance of individualized, multidisciplinary decision-making.References:- Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1557–1564. doi:10.1001/jamaoncol.2023.3759 https://pubmed.ncbi.nlm.nih.gov/37733364/- Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer – primary results of the INSEMA trial. N Eng J Med. 2024. doi:10.1056/NEJMoa2412063.https://pubmed.ncbi.nlm.nih.gov/39665649/- Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794. PMID: 31566680; PMCID: PMC6777230. https://pubmed.ncbi.nlm.nih.gov/31566680/- Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570. https://pubmed.ncbi.nlm.nih.gov/37275963/Sponsor Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode, Jen Delvaux speaks with Courtney Line about her journey after breast cancer, reflecting on the challenges and triumphs experienced four years post-diagnosis. They discuss the importance of community, the impact of lifestyle changes, and the ongoing struggles with health anxiety and hormonal changes. Courtney shares her insights on managing stress, the significance of gratitude, and the lessons learned about relationships during and after treatment. The conversation emphasizes the reality of life after cancer, highlighting both the difficulties and the beauty that can emerge from the experience. You can connect with Courtney here-> https://www.instagram.com/courtney.l.line/ Grounding Sheets we discussed HERE ____________________________________________________________________________  

Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics:  Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy — Laila Agrawal, MD (20:02) Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (25:10) Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer — Zanetta S Lamar, MD (35:03) Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin (46:20) Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy — Justin Favaro, MD, PhD (59:41) Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis — Dr Agrawal (1:05:36) Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop (1:12:00) Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression — Yanjun Ma, MD, PhD (1:23:04) Tolerability Considerations with HER2-Targeted Therapies — Dr O'Shaughnessy (1:29:32) Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma — Erik Rupard, MD (1:46:06) Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging — Kimberly Ku, MD Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease — Richard Zelkowitz, MD (1:49:49) CME information and select publications

Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O'Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer. CME information and select publications here.

In this episode of SurgOnc Today, we discuss the recently updated ASCO guidelines for axillary staging with sentinel lymph node biopsy in breast cancer, as well as considerations for their application in a multidisciplinary setting. This episode is moderated by Dr. Ashley Woodfin from the University of Wisconsin, who is joined by Dr. Clara Park from Brigham and Women's Hospital and Dr. Andrea Abbott from Medical University of South Carolina for a in-depth discussion regarding the guidelines implementation and important considerations.

Julie Stobbe's life took a dramatic turn from Broadway stages to confronting a breast cancer diagnosis, but she transformed adversity into action. Supported by her family, students, and community, she became a beacon of hope and openness. Her leadership in events like Paint the Path Pink now brings strength and awareness to countless others. If this conversation matters to you, share the episode with your family and friends and consider making a donation at therose.org so more women receive breast cancer screening and care. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What is Julie’s background and how did she get started in music? How did Julie transition into teaching in the public school system? How did Julie discover she had breast cancer? Was the mammogram that detected cancer Julie’s first mammogram? What stage was Julie’s breast cancer when it was diagnosed? What treatment did Julie undergo for her breast cancer? How did Julie communicate her diagnosis to her adult children? What role did her school and local community play in supporting Julie during her treatment? How did Julie become involved in the ‘Paint the Path Pink’ event, and what does the event entail? How did Julie share her cancer journey with her students, and what was their response? Timestamped Overview 00:00 From Doctor Dreams to Music 03:15 "From Volunteer to Choir Teacher" 09:17 Finding Humor During Adversity 11:44 "Trust Me, We'll Be Fine" 15:59 Community Fair with Local Support 18:50 Community Support Through Collaboration 23:17 "Building Trust Through Connection" 26:40 "Empowering Women Through The Rose" 28:30 "Embracing Unique Personal Stories"See omnystudio.com/listener for privacy information.

In this episode of Keeping Abreast, Dr. Jenn Simmons is joined by Dr. Susan Brian, an Ivy League–trained endocrinologist, certified menopause specialist, and researcher, to discuss how GLP-1 medications are transforming the treatment of metabolic dysfunction.They explore how therapies like semaglutide and tirzepatide work beyond weight loss, why metabolic disease often goes undiagnosed for years, and how GLP-1s impact diabetes, fatty liver disease, cardiovascular risk, and body composition. The conversation addresses appropriate versus inappropriate use, real risks versus media-driven fear, and why resistance training is essential to protect muscle during weight loss.Dr. Brian also discusses emerging questions around GLP-1s in cancer outcomes and longevity, emphasizing the importance of individualized prescribing, proper screening, and patient education.In This Episode, You'll LearnWhy GLP-1 medications have fundamentally changed metabolic medicineHow GLP-1s compare to older treatments like metforminWho is an appropriate candidate for GLP-1 therapyHow GLP-1–related weight loss may impact breast cancerWhy early screening for metabolic dysfunction mattersHow to preserve muscle while losing weightWhen microdosing or maintenance dosing may make senseHow to avoid common side effects linked to rapid weight lossEpisode Timeline:00:00 Introduction to GLP-1 and Metabolic Health06:32 Appropriate vs. Inappropriate Use of GLP-112:29 Understanding Metabolic Dysfunction18:18 Menopause and Metabolic Health31:42 Understanding Cardiovascular Protection and Hormonal Treatments38:13 The Role of Newer Drugs in Weight Loss and Fatty Liver48:50 The Importance of Appetite Regulation in Weight Management53:26 Microdosing GLP-1s for Longevity: A New Frontier01:00:19 Safe dosing, rate of weight loss, and best practicesTo talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.jennsimmonsmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

Most breast cancers depend on estrogen to grow. This dependence explains why hormone-based treatments, such as aromatase inhibitors, are among the most effective therapies for estrogen receptor–positive breast cancer. Despite their success, these treatments do not work indefinitely for all patients. Over time, many tumors adapt to estrogen deprivation and continue to survive, grow, and spread. This process, known as aromatase inhibitor resistance, represents a major clinical challenge and is often associated with more aggressive disease and poorer outcomes. One reason resistant breast tumors are difficult to treat is that cancer cells adapt their internal signaling systems. Instead of relying on estrogen, they activate alternative growth pathways, including the MAPK and PI3K/AKT pathways. These pathways promote cell survival, movement, and resistance to therapy and are frequently driven by proteins such as KRAS and related G-proteins, which have historically been difficult to target. A recent study published in Oncotarget suggests now that a new class of compounds may offer a way to overcome this resistance. Full blog - https://www.oncotarget.org/2026/01/13/overcoming-aromatase-inhibitor-resistance-in-breast-cancer-a-new-therapeutic-strategy/ Paper DOI - https://doi.org/10.18632/oncotarget.28759 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Abstract video - https://www.youtube.com/watch?v=8xQEilloO9Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28759 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, ROS, MAPK, PI3K/AKT, LTLT-Ca cells To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This bonus episode is the audio from a Breastcancer.org webinar. Follow-up care after breast cancer is essential. Getting good follow-up care can make a big difference in your long-term health and quality of life. In this Breastcancer.org webinar, you'll find out how often you should see your oncologist after your treatment ends and get other practical advice from our expert panelists and patient advocates. Watch the webinar to get expert advice from the panelists, including:  Marisa C. Weiss, MDChief Medical Officer and Founder, Breastcancer.org Hoda Badr, PhDProfessor, Department of Medicine, Baylor College of Medicine Fumiko Chino, MDRadiation Oncologist, Memorial Sloan Kettering Cancer Center Evelyn Robles-Rodríguez, DNP, APN, AOCNDirector of Outreach, Prevention, and Survivorship, MD Anderson Cancer Center at Cooper Erin Roesch, MDBreast Medical Oncologist, Cleveland Clinic Megan-Claire ChaseBreast Cancer Program Director, SHARE Cancer SupportPatient Advocate Amanda HelmsPatient Advocate Kate RosenblumPatient Advocate Loriana Hernandez-AldamaTwo-Time Cancer Survivor, Award-winning Journalist, Author

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PTK865. CME/MOC/NCPD/AAPA/IPCE credit will be available until January 16, 2027.Forging New Paths With Earlier Use of ADCs in Breast Cancer: From Clinical Breakthroughs to Improved Outcomes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

Lakysha was diagnosed with breast cancer in 2018. Her cancer was caught early but test results showed there was a high chance of recurrence. She required surgery, chemotherapy, radiation and a hormone blocker for five years. She also had a hysterectomy to minimize her risk of other cancers. Life is a journey for her, filled with ups and downs, new challenges and triumphs. And Vonya is the friend we all need. She's the friend who helps you reframe your bad days and encourages you to focus on something that brings you joy. She helped Lakysha normalize what she was going through and accept her emotions as they came. She's also the friend who reminds you not to let one bad day spill into the next day.

Cancer is a club you never want to belong to, but you find the most amazing people when you do. Erica Campbell has a group of women who bonded over their breast cancer journey. Together they know what it means to face illness head-on -- to confront mortality, search for strength, and build the resilience required to move forward. As a breast cancer survivor who also lost her mother to the disease, Erica speaks the 'vocabulary of cancer' from multiple perspectives. In her debut memoir, The Mastectomy I Always Wanted, she pairs honesty and vulnerability with practical, compassionate guidance for anyone navigating the mastectomy experience.   You Are Not Alone At first it may feel like you are walking this path by yourself, but in time you will attract the people meant to support you and walk beside you. It may take a while, but some people care and want to help. Be intentional and rigorous in seeking out those you need. Knowledge is power, and community is contagious. Small Steps Create Hope "Sometimes during my journey, I allowed myself 24 hours to fully feel sadness or grief. After that, I made myself do anything that felt like the next right thing. Even tiny actions—brushing my hair, taking a walk around the block—gave me a sense of accomplishment. When self‑pity crept in, I quieted my mind and listened for the small inner voice guiding my next step. I learned that even the smallest amount of patience and progress can create hope."   CLICK HERE TO BUY   An instant Amazon Best Seller in Breast Cancer, General Women's Health, and Genetic Health! In this breast cancer book for women, Erica Neubert Campbell shares an intimate and encouraging story of her double mastectomy journey. This is a powerful companion guide for women navigating the choice to have a mastectomy or a lumpectomy. Empower yourself with this supportive resource to build trust and resilience–from the day you are diagnosed to the moment you realize: "I got this." Choosing a mastectomy is more than losing your original breasts. It is about the power of self-discovery, personal choice, and mindset. In this book, you will learn that removing fear is just as important as removing cancer. Women and caregivers will understand that a double mastectomy is an outer journey of physical change and an inner journey of mental strength. "Are you okay with seeing my breasts?" Before her double mastectomy, a friend showed Erica her reconstructed breasts—and it changed everything. This rare moment of vulnerability allowed Erica to visualize the future and shift to a more hopeful perspective. Erica now pays this act forward with a candid and uplifting portrait of the mastectomy journey. Whether you are making your choice following a breast cancer diagnosis or a discovery of the BRCA gene, this mastectomy memoir will encourage you to trust yourself, accept your new body, and build resilience through tough times. Caregivers will gain a deeper understanding of the emotions of the diagnosis that are otherwise hard to describe. In this resource, discover:       Empowering mastectomy book for women recently diagnosed with breast cancer or carrying the BRCA gene       Over fifty candid photos of the mastectomy recovery experience       Honest and authentic emotions around the challenges of a breast cancer diagnosis       Inspiration and tools for building strength in the double mastectomy journey       Insights for breast cancer caregivers, family, and friends—granting them the power to support their loved one with compassion and understanding Erica Neubert Campbell, breast cancer survivor and longtime cancer advocate, shares this mastectomy memoir to provide healing and hope. The Mastectomy I Always Wanted is a must-read for women who are determined to rebuild their lives stronger than ever. If you're seeking a source of breast cancer inspiration as you explore a double mastectomy and reconstructive surgery, read this book.   Connect with Erica Here   Website   Instagram   Linkedin   Facebook    

Tired of repeatedly stopping and starting the same “bad” nutrition habits after breast cancer? Isn't it exhausting? In Part 2 of Breast Cancer Nutrition Habits: The Clarity Series, learn how to acknowledge and stop unhelpful nutrition habits without guilt or shame, so you can move toward eating with peace and enjoying your food again! Breast Cancer Nutrition Habits: The Clarity Series (Part 2) helps breast cancer survivors identify and stop unhelpful eating habits that increase food anxiety and trigger feelings of failure . In this episode, I share why acknowledging unhelpful nutrition habits helps overcome striving for perfection, how stress, hormone therapy side effects, and fear of recurrence can drive unhealthy food behaviors, and what it really means to stop habits that no longer support your physical or emotional well-being; without self-judgment. This episode is for breast cancer survivors who want clarity, confidence, and peace around food, without restriction or perfectionism. After today's episode you'll understand:How to acknowledge unhelpful breast cancer nutrition habits without guilt or shame __________________________________________________________Click here to get the KEEP, STOP, START Plan Worksheet Click here to apply to my Peaceful Plate program! Follow me on Instagram @hormone.breastcancer.dietitian

Physician-scientist Randall Stafford studies the effects of alcohol use on population health – the true health impact, he emphasizes. Stafford explains how early research suggested that drinking is beneficial – or at least not bad – for people. That mindset produced decades of wishful thinking based on inconsistent science driven by social, emotional, and industry forces. The small cardiovascular benefits, he says, are far outweighed by the risks of cancer, liver disease, depression, and other ills. Although the harms of low-level consumption are small, there is no safe level of alcohol use, Stafford tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Randall StaffordConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Randall Stafford, a professor of medicine at Stanford University.(00:03:35) Challenges in Alcohol ResearchWhy cultural norms and study limitations complicate evidence.(00:03:56) Historical Perspectives on DrinkingHow early studies suggested benefits and why those conclusions shifted.(00:09:12) Risk, Dose, and Drinking PatternsThe increased risks with binge drinking and higher doses of alcohol.(00:12:15) Health Benefits vs. Lifestyle EnjoymentClarifying what alcohol does—and does not—provide medically.(00:13:37) Alcohol and Mental HealthThe bidirectional effects between alcohol use and mental health.(00:17:37) Broader Mental and Social EffectsAlcohol's connection to bipolar disorder, unemployment, and social harm.(00:20:12) How Alcohol Myths PersistWhy simplified conclusions endured despite contradictory data.(00:22:46) Changing Cultural AttitudesCultural trends toward reduced drinking and alcohol-free periods.(00:25:49) Alcohol and Liver DiseaseThe effects of alcohol beyond heavy use, including metabolic disease.(00:27:29) Strategies to Reduce HarmWay to reduce alcohol consumption and avoid binge drinking.(00:29:25) Future In a MinuteRapid-fire Q&A: avoiding alcohol, research needs, and studying liver disease.(00:31:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics:  Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued — Alan Astrow, MD (6:47) Previously Untreated Metastatic TNBC (mTNBC) — Prof Schmid (10:47)  Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan — Jennifer Yannucci, MD (27:19) Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) — Ranju Gupta, MD; Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol — Yanjun Ma, MD, PhD (31:35) Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Sharma (36:31) Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission — Dr Gupta; Case: Management of neutropenia associated with sacituzumab govitecan — Gigi Chen, MD (50:30) Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease — Dr Gupta; Case: Management of T-DXd-related side effects — Laila Agrawal, MD (54:10) Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC — Dr Nanda (58:59) Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd — Atif M Hussein, MD, MMM (1:12:40) Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés (1:18:10) CME information and select publications

In this episode, Dr. Sanda Moldovan interviews Katrina Faux, a functional practitioner who healed her breast cancer naturally. They discuss the increasing rates of breast cancer, the importance of holistic approaches, and the role of emotional trauma in cancer development. Katrina shares her personal journey, the detoxification process, and the impact of mold and heavy metals on health. They also explore the significance of functional testing, dietary approaches, and the connection between oral health and cancer. Katrina emphasizes the need for empowerment and education for clients dealing with cancer, and she offers resources for prevention and healing. Want to see more of The Holistic Dentistry Show? Watch our episodes on YouTube! Do you have a mouth- or body-related question for Dr. Sanda? Send her a message on Instagram! Remember, you're not healthy until your mouth is healthy. So take care of it in the most natural way.  Key Takeaways: Chapters (00:00) Introduction and Personal Updates (02:59) Katrina's Journey with Breast Cancer (05:53) The Role of Emotional Trauma in Cancer (08:51) Deciding on Natural Healing Methods (11:49) Detoxification and Its Importance (14:37) Navigating Heavy Metals and Mold Exposure (17:52) Monitoring Health Post-Remission (20:50) Helping Others Through Their Cancer Journeys (23:51) Innovative Screening and Prevention Techniques (27:45) The Role of Oral Health in Cancer (29:52) Detoxification Strategies for Cancer Patients (32:52) Dietary Approaches to Cancer Treatment (35:28) Challenges in Alternative Cancer Treatments (37:47) Proactive Measures for Cancer Prevention (40:20) Resources for Cancer Patients Guest Info: Instagram: https://www.instagram.com/katrinafoe/ YouTube: https://www.youtube.com/@cancerfreedom Facebook: https://www.facebook.com/nutritional.pilates Connect With Us:  AskDrSanda | YouTube BeverlyHillsDentalHealth.com | Instagram  DrSandaMoldovan.com | Instagram  Orasana.com | Instagram  

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.CME information and select publications here.

At 39, Hollye Jacobs went in for a routine mammogram and received a life-changing breast cancer diagnosis—suddenly moving from caregiver to patient. In this deeply human conversation, Hollye, a nurse, social worker, and resilience coach, shares how she navigated treatment with intention rather than panic, drawing on both clinical expertise and lived experience.We talk about advocating for yourself, assembling the right medical team, why a cancer diagnosis feels urgent (and often isn't), and the importance of palliative care, nutrition, psychosocial support, and psychosocial support. Hollye also explains why children should be included—not shielded—in a family's cancer journey, and how honest, developmentally appropriate communication can reduce fear.At the heart of the episode is Hollye's concept of “silver linings”—not forced positivity, but small moments of balance that help carry us through hard days. From reframing language like “yet” to redefining resilience as adaptation and transformation, Hollye offers practical tools for navigating life's hardest seasons.Whether you're navigating illness, caregiving, or a major life transition, this conversation offers tools you can return to again and again. Tune in to hear how resilience can be practiced—and how even the smallest silver linings can make a meaningful difference.Hosted on Ausha. See ausha.co/privacy-policy for more information.

In this episode of Keeping Abreast, Dr. Jenn Simmons sits down with Dr. Joseph Dituri, a biomedical engineer, hyperbaric medicine specialist, and former U.S. Navy saturation diver, to explore the science of healing, aging, and human resilience.Drawing from his clinical work in hyperbaric medicine and his recovery from a traumatic brain injury, Dr. Dituri explains how oxygen, pressure, and controlled physiological stress affect inflammation, sleep quality, immune function, and cellular repair. Together, they examine the evidence behind biological versus chronological age, the role of muscle and bone health in longevity, and the evolving, evidence-informed use of hyperbaric oxygen therapy in healing and cancer support. In This Episode, You'll Learn:What happens to the human body when it lives under pressure for 100 days underwaterHow hyperbaric oxygen therapy impacts inflammation, immune function, sleep, and agingThe difference between biological age vs. chronological age and why it matters.Why muscle and bone health are critical pillars of longevityHow healthy stress can strengthen the brain, body, and immune systemThe science behind collagen synthesis, stem cells, and tissue repairWhat the research actually says about hyperbaric medicine and cancerHow to identify qualified, safe hyperbaric centers and avoid poorly run facilitiesEpisode Timeline Highlights:00:00 Introduction to Dr. Joe Dituri and His Mission03:08 What Hyperbaric Medicine Is and How It Works05:54 Why He Chose to Live Underwater for 100 Days08:54 Daily Life, Work, and Challenges Beneath the Ocean11:53 Sleep, Brain Function, and Cognitive Changes Under Pressure14:53 Inflammation, Telomeres, and Measuring Cellular Health18:05 The Core Science Behind Hyperbaric Oxygen Therapy28:50 Isolation, Connection, and Human Biology33:49 Biological Age vs. Chronological Age50:35 Hyperbaric Therapy for Health Optimization53:17 Collagen, Tissue Healing, and Regeneration56:07 Hyperbaric Medicine and Cancer Support01:06:50 Treatment Frequency, Duration, and Expectations01:12:03 How to Find Safe and Qualified Hyperbaric Centers01:15:52 Longevity, Optimization, and What's NextWhere to Find Dr. Joseph Dituri (Dr. DeepSea)Website: https://drdeepsea.com/Instagram: www.instagram.com/drdeepseaTo talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.realhealthmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

Send us a textDr. Jenn Simmons spent nearly two decades as a board-certified breast surgeon working inside conventional oncology. Then her own health crisis forced her to question the system she had been trained to defend and ultimately walk away from it.Dr. Kevin White sits down with Dr. Simmons to unpack how that turning point reshaped her understanding of breast cancer, prevention, and what real health protection looks like for women. She shares why focusing solely on tumors misses the bigger picture, how inflammation and environment quietly shape risk long before diagnosis, and why many standard screening practices deserve closer scrutiny.In this episode, you'll hear why “We're very good at reacting to disease. We're much worse at asking what created it,” how medical dogma can persist even when data says otherwise, and what safer, more respectful approaches to screening and prevention can look like when women are treated as individuals rather than protocols.If you've ever felt confused, pressured, or dismissed when making decisions about breast health, this conversation offers a calmer starting point: one rooted in information, agency, and long-term wellbeing.You can learn more about Dr. Jenn Simmons' work at jennsimmonsmd.com and perfeqtionimaging.com, and follow her on social media at @drjennsimmons. For the AURIA breast health test discussed in this episode, visit auria.care and use code DRJENN20.If you enjoyed this episode, follow The Daily Apple and leave a review. It helps more people find the show. Learn more at www.primehealthassociates.com and follow Dr. Kevin White on Instagram at @KevinWhiteMD. Prime Health Associates

I wanted to take this first episode of 2026 to reflect on the last 104 episodes over the past almost 2 years of the show. There have been some amazing conversations and incredible humans that I've had the absolute pleasure of chatting with. I'm sharing some of the highlights and great things so many of my guests have accomplished, all during or after a cancer diagnosis. I hope you enjoy this look back and remember with me, while also looking forward to what's to come in 2026. Below are some of the books and non-profits we mentioned. Please check them out!! Happy New Year!!BooksFlat Please by Ellyn Winters The Unlikely Gift of Breast Cancer by Diane SimardThe Guys Guide to Everything Breast Cancer by Rick BakerWelcome to Katie's Brain by Katie SmithLight Through Darkness by Harriet CabellyPositively Altered by Dr. Cindy HowardOvercoming Life's Toughest Challenges by Andy CampbellBut is it the Bad Kind by Rachel Orgel Boo Bear's Big Day by Jodi NovakCancering by Lauren HuffmasterCancer Ramblings by Sandy DuarteCancer Stories of Hope by Kevin DonaghyA Breast Cancer Journey by Jennifer DouglasI AM ALIVE by Nathalie LathamFinding Hope and Joy in Cancer by Amanda GunvilleNon-Profitshttps://www.hodgkinsinternational.com/https://www.surviveandthrivecr.org/ https://liveradvocates.org/https://imermanangels.org/https://theolandusfoundation.org/https://adventurefound.org/https://www.myeloma.org/https://www.prostatenetwork.org/https://malebreastcancerhappens.org/https://testicularcancersociety.org/https://www.sitesandinsights.org/https://beckybakerfoundation.org/https://www.facebook.com/thecrownandgloryproject/?locale=tl_PH https://askellyn.ai/https://twistoutcancer.org/https://epicexperience.org/https://www.theboobytrapfoundation.org/

Dr. Jenn Simmons joins the Biohacker Babes for a powerful and deeply personal conversation about her shift from conventional oncology to functional medicine after witnessing the impact of breast cancer in her own family. She pulls back the curtain on the limitations of traditional cancer care — especially the overreliance on mammograms — and explains why true prevention begins with metabolic health, lifestyle choices, informed patient advocacy, and other options for testing. Dr. Jenn challenges the profit-driven structure of the healthcare system and empowers listeners to question standard protocols, explore more predictive screening options like the Auria test, and reclaim responsibility for their wellbeing. This episode is a bold call to action for anyone ready to move beyond fear-based medicine and step into proactive, root-cause healing.Dr. Jenn Simmons is a breast surgeon, integrative oncologist, best-selling author, Podcast Host, 3x Summit host and founder of PerfeQtion Imaging. She began her career as Philadelphia's first fellowship-trained breast surgeon and spent 17 years at the forefront of breast oncology.Her own health crisis led her to discover functional medicine and a new framework for patient care—one focused on creating health rather than managing disease. In 2019, she left conventional medicine to establish Real Health MD, where she helps women on their breast cancer journey truly heal.Today, her mission is to transform the landscape of breast cancer detection and survivorship. Through innovations in functional imaging, hormone restoration, and integrative care, Dr. Simmons aims to revolutionize how we screen for breast cancer and to redefine longevity for all women, including those with a history of breast cancer.SHOW NOTES:0:40 Welcome to the podcast!2:06 About Dr. Jenn Simmons3:02 Welcome Dr. Jenn to the show!3:46 Her turning point from conventional care7:26 Dr. Mark Hyman & functional medicine9:45 Conventional whack-a-mole17:26 Dad's transition into Biological Dentistry20:19 Metabolic chaos in children23:45 Cholesterol & metabolic health32:25 Mammograms & radiation35:55 History & stats on mammography43:02 We all make cancer cells44:27 Diagnosis mindset46:33 Renee's screening53:28 Alternative screening options58:39 Perfeqtion Imaging centers1:00:04 The Galleri Test1:07:48 Changing the system1:10:24 Where to find her1:11:49 Her final piece of advice1:12:50 Thanks for tuning in!RESOURCES:Website: www.perfeqtionimaging.com, www.realhealthmd.comYouTube: @dr.jennsimmonsIG: @drjennsimmons Auria Tears Test - code: DRJENN20Support this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

There is no way around it, breast cancer is hard. But as our guest today will tell you, trying to remain upbeat throughout treatment can have a positive impact on your life. Amy Elizabeth Chalmers Hicks brings a unique perspective. She was adopted so she doesn't know her biological family's health history, leaving her to navigate two cancer diagnoses without the insights many rely on to understand risk. However, despite these unknowns, when she found a lump, she stayed at ease, started treatment right away, surrounded herself with people who were loving and supportive and made a deep commitment to keeping a positive attitude. She is here today to share her inspiring story with us.

Have you ever wondered why you stay stuck in the same unhelpful nutrition habits, year after year? Eating to potentially reduce your recurrence risk isn't just following food rules or structured diets; it's getting crystal clear and brutally honest about your own nutrition habits. Identifying habits that serve you, those that don't, and understanding what's truly possible for you to achieve with your food choices after cancer is the key to ending your worry about every bite you take. Even after finishing breast cancer treatment and promising yourself you'd eat perfectly, let's be honest. . .you're not sticking with that breast cancer eating plan you swore you'd follow. But what if you're already doing amazing things to support your breast health with your post-treatment diet, but you just don't realize it? Whether you finished treatment in the last five weeks, months or years, after today's episode you'll understand:Why you already have great breast cancer nutrition habits, but you discount their impactThree reasons why you overlook your “second-nature” breast cancer nutrition habitsThe way “brainwashing” has you chasing breast cancer nutrition perfection________________________________Click here to get the Keep, Stop, Start Plan Worksheet!Click here to apply to my Peaceful Plate program! Follow me on Instagram: @hormone.breastcancer.dietitian

A deluxe edition of The Sprina Sessions is live! Join Keila and Jasmine as they discuss all things Beyond The Gates and Trina Robinson on General Hospital. The Rundown Includes: Anita begins her breast cancer treatment before breaking the news to Dani and Nicole on New Year's Eve, Chelsea and Naomi walk in on a sensitive conversation, Bill and Dani's connection rattles Vernon, Kat makes a choice that could impact her health in the future,  Bill offers pearls of wisdom to Anita. Dani gives Vernon the space to break down and let it all out, Trina makes a New Year's Resolution, and Curtis and Jordan reignite their relationship. The show wraps with Trina Speculations for the week ahead and the Song Picks of the Week. Enjoy!Sprina Sessions Playlist Song Selections:Unconditional - Jade Follow Keila on X and Blue Sky: https://x.com/LadyWrestlingXhttps://bsky.app/profile/ladywrestlingx.bsky.socialFollow Jasmine on X and Blue Sky: https://x.com/twin_fangirlhttps://bsky.app/profile/twinfangirl.bsky.socialCreate your podcast today! #madeonzencastr

Love the episode? Send us a text!What happens when breast cancer comes back — even after doing “everything right”?In this deeply honest conversation, Laura Carfang sits down with Teresa Baglietto, a four-time cancer survivor, author, and podcast host, to talk about what it really means to live with cancer recurrence, fear, and long-term survivorship.Teresa shares what it felt like to discover her first breast cancer lump (“it was like a block of cement”), how she navigated a recurrence after bilateral mastectomy, and the treatment decisions that ultimately saved her life — including why she chose not to take chemotherapy or tamoxifen.Together, Laura and Teresa explore the emotional and practical realities of survivorship: fear of recurrence, making medical decisions without complete information, balancing career and health, and finding purpose after cancer.This episode is for anyone newly diagnosed, living with metastatic or recurrent disease, or learning how to live after cancer — when the world expects you to “move on,” but your body and mind remember everything.In This Episode, We Talk About:What a breast cancer lump can actually feel likeBeing diagnosed after delaying a mammogramBreast cancer recurrence after mastectomyRadiation vs chemotherapy and treatment decision-makingOncotype DX testing and personalized careSaying no to tamoxifen after severe side effectsFear of recurrence and how it shows up years laterHow cancer reshapes career, identity, and purposeWhy having a plan can help you survive the unknownFinding meaning and community after diagnosisAbout Our GuestTeresa Baglietto is a four-time cancer survivor, author of The Ripple Effect, and host of the podcast InShok. Her work focuses on resilience, leadership, and navigating life's hardest moments with intention and courage.Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.

Cold and flu season can feel extra challenging after breast cancer, especially when energy is already low after the holidays. In Episode 444, Laura shares gentle, practical ways to support your immune system during winter without fear or pressure. You will learn how the immune system works, why it is not meant to stay activated, and how sleep, stress, and hormone shifts influence immune health. Laura also discusses seasonal food wisdom, herbs and spices, movement during winter, emotional care, and how making choices from self-love supports resilience. This episode focuses on nourishment, rest, boundaries, and compassion rather than perfection or control.   Resources: Everyone's Table: Global Recipes for Modern Health  https://amzn.to/3Nb70eF   Let's Connect! If this episode helped you breathe a little easier, please share it with a friend or leave a review. Every share helps spread this message of hope, healing, and whole-person wellness.

What do you think of serrapeptase for reducing coronary plaque?We were told to get a TDAP vaccine or we wouldn't be able to see our new grandchild for 8 weeks!Do I have lupus?Which supplements tend to reduce negative effects of X-rays?

The Holiday Season in NYCPeanut allergies cause and effectWhich calcium supplements can I take if I'm allergic to cow protein?Can my husband take saw palmetto in lieu of his prostate medications?What do you think of traction to help bulging discs?What is your take on green powder supplements?

Jenna shows the best of amazing women as she and singing superstar Ciara help viewers with their relationship dilemmas. Also, Malala Yousafzai discusses her new memoir, "Finding My Way". Plus, Penn State coach Katie Schumacher-Cawley discusses her battle with breast cancer. And, Melba Wilson stops by to share two delicious dishes, a pulled pork chicken sandwich and sweet potato pie. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Men often don't think of themselves as having breasts. For men, it's their chest or their “pecs.” So it may come as a surprise to learn men are at risk of breast cancer. The fact is men have breast tissue and can get breast cancer. In the U.S., less than 1% of all cases occur in men, but it does happen. Today we are joined by Jake Messier, a man living with metastatic breast cancer, after being misdiagnosed twice and finally learning in August 2024 that it had advanced. Jake openly shares his story across active social media platforms and is dedicated to spreading awareness of male breast cancer, as well as the distinct mental and physical health struggles that go largely unaddressed when a man is navigating what is typically seen as a woman's disease.

This episode originally dropped in October, 2024Dr. Dawn Mussallem joins Rip for an enlightening discussion on the vital role of personalized precision lifestyle medicine in breast cancer prevention and recovery. They dive deep into the importance of nutrition, emphasizing whole food plant-based diets, supplements, and the power of social connections in enhancing health outcomes. Dr. Mussallem shares her insights on various supplements, including the benefits and risks associated with Vitamins D, B12, and the impact of iron during cancer therapies, alongside the benefits of herbs and spices like turmeric and ginger in supporting overall health. The conversation also highlights the significance of sleep hygiene, social connections, and managing stress. While there is no "one size fits all" approach to cancer treatment and recovery, this episode aims to empower listeners to ask questions, seek knowledgable physicians, and prioritize overall physical and emotional health in their recovery.Register for our 2026 April Black Mountain, NC retreat - from now until January 10th, 2026, use code PODCAST for $300 offListen to Part 1 of this Podcast SeriesEpisode WebpageWatch the Episode on YouTube